Quote:

---

If you have a significant percentage of the patients enrolled in the trials that do not actually have the disease that you’re seeking to treat your trial will fail. And that’s what’s happening over and over again. As a result I think Eli Lilly is the group that made the real first stab at the diagnostic space by buying Avid RadioPharmaceuticals for 800 million dollars with 300 million dollars upfront specifically because Avid RadioPharmaceuticals had a diagnostic test that was available under the CLIA framework that had achieved a certain level of research activity where they felt they could use it as a companion diagnostic for their therapeutic programs. We very much want to follow in those footsteps.

---